Despite the absence of selective CK1 inhibitors in clinical trials, umbralisib, a dual inhibitor of PI3Kδ and CK1ε, is currently being evaluated in clinical trials for patients with chronic lymphocytic leukemia (CLL) (37) and non-Hodgkin lymphomas (NHL) (38). Here, CSNK1A1 is linked to B-cell chronic lymphocytic leukemia.